Opinion|Videos|March 21, 2025
Examining Uncomplicated UTI Recurrence
Panelists discuss how uncomplicated urinary tract infection (UTI) recurrence affects 20% to 30% of female patients within 6 months of initial infection, with contributing factors including anatomical variances, hormonal changes, genetic predisposition, insufficient treatment duration, resistant pathogens, and biofilm formation that persists despite proper adherence to standard antibiotic protocols.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How common is recurrence of uncomplicated UTIs across various patient populations, and what factors contribute most to recurrences despite adherence to standard treatments?
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention
2
Trends in Pharmacy Benefit Manager Market Dynamics, 2016-2025
3
Tarlatamab Plus Durvalumab Cuts Risk of Death by 58% as First-Line Maintenance in ES-SCLC
4
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
5